Clinical trial

Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)

NCT00393705

Study summary

ClinicalTrials.gov

Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Insulin Biphasic Aspart 30/70 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention insulin lispro LM Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention insulin lispro MM Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention insulin lispro LM Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-10-01

PhasePHASE4

Conditions

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Interventions

Insulin Biphasic Aspart 30/70DRUG

insulin lispro LMDRUG

insulin lispro MMDRUG

insulin lispro LMDRUG

Sponsors & collaborators

Eli Lilly and Companylead sponsor

Mapped research locations

IstanbulTurkey (Türkiye)1 BucharestRomania1 BialystokPoland1 ZagrebCroatia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00393705 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.